TRDA — Entrada Therapeutics Share News
0.000.00%
Last trade - 00:00- $171.71m
- -$51.29m
- $25.42m
Brief: Entrada Therapeutics Inc - Approves Strategic Plan Focusing On DMD Programs - SEC Filing
Entrada Therapeutics rises on UK approval for muscle-wasting drug study
U.S. STOCKS ON THE MOVE-Starbucks, Bristol Myers Squibb, Home Depot
U.S. STOCKS ON THE MOVE-BioMarin, Azul, Sun Communities
U.S. STOCKS ON THE MOVE- Twilio, Bath & Body Works, Wingstop
Entrada rises as FDA removes clinical hold on muscle-wasting therapy
Entrada Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Entrada Therapeutics Inc expected to post earnings of 14 cents a share - Earnings Preview
Entrada Therapeutics Inc expected to post earnings of 14 cents a share - Earnings Preview
Brief: Entrada Therapeutics Announces $100 Million Registered Direct Offering
Brief: Entrada Therapeutics Reports Positive Preliminary Data From Phase 1 Entr-601-44-101 Trial
Entrada Therapeutics Inc reports results for the quarter ended in January - Earnings Summary
Entrada Therapeutics Inc expected to post earnings of 12 cents a share - Earnings Preview
Entrada Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Entrada Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Entrada Therapeutics Promotes Nathan Dowden To President
U.S. STOCKS ON THE MOVE-Virgin Galactic, Boeing, Zscaler
Entrada falls as FDA keeps muscle-wasting therapy on clinical hold
Brief: Entrada Therapeutics Announces Updates On Entr-601-44 In Duchenne Muscular Dystrophy